Publication of Sustainability Report 2026
August 3, 2026 – Osaka, Japan - Santen Pharmaceutical Co., Ltd. (hereinafter Santen) today announced the release of both the Japanese and English versions of its “Sustainability Report 2026”.
Guided by its Core Principle, Santen places the creation of social value through the preservation and enhancement of eye health at the heart of its sustainability initiatives. Santen will continue to communicate with stakeholders as it strives, under the organizational capability of Santen Commercial Excellence*, to become a leading ophthalmology company, earning the trust of patients and the global ophthalmic community while aspiring to realize “Happiness with Vision” by providing products and services that are of value to patients, consumers, and medical professionals worldwide.
“Sustainability Report 2026” provides a comprehensive overview of Santen’s sustainability policies, initiatives, and activities, enabling a broad range of stakeholders to gain a deeper understanding of the Company’s approach to sustainability. Through this report, Santen hopes to further promote dialogue with stakeholders and leverage their feedback so that it can continuously enhance its business operations and sustainability initiatives.
This edition of the report covers activities through fiscal year 2025 and will be updated as necessary in the future.
The report is available on Santen’s sustainability website:
* Santen Commercial Excellence: Organizational capabilities for leveraging synergies among Santen’s strengths in originating products and maximizing product value to effectively drive results
About Santen
Santen is a global pharmaceutical company committed to advancing eye health and improving lives through better vision. Founded in 1890 in Osaka, Japan, Santen makes use of more than 135 years of experience in research and development, manufacturing, and marketing of pharmaceuticals and medical devices to help people around the globe maintain and improve their eye health. Santen focuses exclusively on eye health and its portfolio includes glaucoma, dry eye, infection, allergy, age-related macular degeneration, and myopia. Santen’s products and services are available in more than 60 countries and regions. Guided by its Core Principle “Tenki ni sanyo suru” – Exploring the secrets and mechanisms of nature in order to contribute to people’s health – Santen combines its expertise with deep patient focus to contribute to the realization of “Happiness with Vision.”
For more information, please visit https://www.santen.com/en.
Contact
Corporate Communications
Santen Pharmaceutical Co., Ltd.
E-mail: communication@santen.com
